Bioregulator Cardiovascular

Research Benefits

• Vascular Endothelial Support: Investigated for its role in maintaining endothelial cell integrity and supporting healthy vascular tone in aging tissue models
• Blood Pressure Regulation Research: Studied in the context of renin-angiotensin system modulation and vascular smooth muscle relaxation pathways
• Cardiac Tissue Homeostasis: Explored for protective effects on cardiomyocytes under oxidative stress and ischemia-reperfusion conditions
• Age-Related Vascular Decline: Research from Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology suggests bioregulatory peptides may restore protein synthesis in aging cardiovascular tissue
• Atherosclerosis Research: Investigated for potential modulation of lipid metabolism and inflammatory marker expression in vascular walls

Mechanism of Action

Cardiovascular bioregulator peptides belong to the class of short regulatory peptides characterized by Khavinson's research program. These di- and tripeptides interact with specific DNA sequences in promoter regions of genes responsible for protein synthesis in cardiovascular tissue.

Key Pathways

• Gene Expression Modulation: Binds to complementary DNA regions in endothelial and smooth muscle cells, restoring age-suppressed transcription of structural and functional proteins
• Epigenetic Regulation: Research indicates these peptides may modulate chromatin condensation states, enabling access to previously silenced gene regions in aging tissue
• Endothelial Nitric Oxide Pathway: Studied for upregulation of eNOS expression and downstream vasodilatory signaling
• Antioxidant Defense: May promote expression of SOD, catalase, and glutathione peroxidase in cardiac tissue, supporting endogenous antioxidant capacity

Unlike pharmacological vasodilators, bioregulatory peptides are theorized to act at the gene expression level, potentially offering more sustained normalization of cardiovascular function rather than acute symptomatic effects.

Research Protocol

For research purposes only. Not for human consumption.

Published Research Parameters

• Typical Research Dose: 10-20 mg per administration in preclinical models
• Administration Route: Subcutaneous injection in most published protocols
• Research Cycle: 10-20 day cycles commonly reported in bioregulator literature
• Frequency: Once daily administration in most study designs

Reconstitution

• Reconstitute with bacteriostatic water
• Gently swirl; do not shake vigorously
• Use within 30 days of reconstitution when stored at 2-8 °C

Safety & Storage

Storage Requirements

• Lyophilized: Store at -20 °C for long-term stability; stable at 2-8 °C for up to 12 months
• Reconstituted: Refrigerate at 2-8 °C; use within 30 days
• Protect from light and repeated freeze-thaw cycles

Research Considerations

• Bioregulator peptides are generally reported as well-tolerated in published preclinical studies with a wide safety margin
• No significant adverse effects documented in Khavinson's extensive publication record spanning 40+ years of bioregulator research
• Not recommended for combination with anticoagulant or antihypertensive compounds without thorough protocol review
• All peptides are for research use only

Frequently Asked Questions

• What is a cardiovascular bioregulator peptide?

  It is a short regulatory peptide derived from research into tissue-specific gene expression modulators. Developed as part of Khavinson's bioregulation program at the St. Petersburg Institute of Bioregulation and Gerontology, these peptides target cardiovascular tissue protein synthesis pathways.

• How does it differ from pharmaceutical cardiovascular agents?

  Unlike drugs that block specific receptors or enzymes, bioregulatory peptides are theorized to work at the gene expression level, potentially restoring the tissue's own capacity for normal protein production rather than providing symptomatic relief.

• What purity is this product?

  All BeaCapra peptides are manufactured to ≥99% purity with full HPLC and mass spectrometry verification. A Certificate of Analysis is available for every batch.

• Can bioregulators be combined in research?

  Khavinson's published research frequently employs multi-organ bioregulator protocols. The cardiovascular bioregulator is commonly studied alongside thymic and pineal bioregulators for systemic aging research.

• What is the research basis for bioregulators?

  Over 40 years of published research, primarily from Russian and European institutions. Khavinson's work includes studies on peptide-DNA interactions, epigenetic regulation, and tissue-specific protein synthesis restoration.